Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olga Mulas

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Experimental Hematology|February 6, 2013
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patientsGiorgio La Nasa, Giovanni Caocci, Roberto Littera, et al.
Leukemia Research|August 26, 2017
HLA-G molecules and clinical outcome in Chronic Myeloid LeukemiaGiovanni Caocci, Marianna Greco, Marcella Arras, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Experimental Hematology|August 27, 2015
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patientsGiovanni Caocci, Bruno Martino, Marianna Greco, et al.
Journal of Public Health Research|May 7, 2021
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort studyFederica Sancassiani, Elena Massa, Carla Pibia, et al.
Frontiers in Oncology|February 18, 2022
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, et al.
Frontiers in Oncology|February 11, 2026
The role of satisfaction with care among factors affecting health-related quality of life in people with cancer: a cross-sectional studyFederica Sancassiani, Goce Kalcev, Mirian Agus, et al.
Annals of Hematology|May 3, 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practiceGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Experimental Hematology|February 6, 2013
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patientsGiorgio La Nasa, Giovanni Caocci, Roberto Littera, et al.
Leukemia Research|August 26, 2017
HLA-G molecules and clinical outcome in Chronic Myeloid LeukemiaGiovanni Caocci, Marianna Greco, Marcella Arras, et al.
Frontiers in Oncology|December 4, 2025
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologistsMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Experimental Hematology|August 27, 2015
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patientsGiovanni Caocci, Bruno Martino, Marianna Greco, et al.
Journal of Public Health Research|May 7, 2021
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort studyFederica Sancassiani, Elena Massa, Carla Pibia, et al.
Frontiers in Oncology|February 18, 2022
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, et al.
Frontiers in Oncology|February 11, 2026
The role of satisfaction with care among factors affecting health-related quality of life in people with cancer: a cross-sectional studyFederica Sancassiani, Goce Kalcev, Mirian Agus, et al.
Annals of Hematology|May 3, 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practiceGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
British Journal of Haematology|January 11, 2026
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort studyMassimo Breccia, Valentina Giai, Tiziana Rosso, et al.
Cell Death & Disease|June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemiaMohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Pageof 6